Abstract
Fuji-Keizai U.S.A. published a market research report on the biochip business
in August 2006. Since that early report, more than 18 months have passed and
the biochip business has continued to change at a fast pace.
We study the biochip business extensively, analyzing where marketplace change
is most intense and reporting the trends, new fields of use, and the global
market prospects for companies seeking to gain or reclaim market share or
strengthen their market positions.
Our research objectives within the biochip segment are DNA/RNA chips, devices,
software and services; Lab-on-Chip devices and services; Protein
chips/devices; and Special-Purpose Biochips.
This report discusses new biochip products now reaching the market. DNA/ RNA
products discussed include high-density tiling, copy number variation, SNPs,
alternate splice variant, ChIP-Chip, CpG island, DNA methylation, microRNA,
molecular diagnostic biochips and related areas such as sequencing. New
lab-on-a-chip/ microfluidic biochips for Point-of-Care (POC) diagnostics,
through credit card-size devices for liquid chromatography or for drug
discovery optimization, will be reviewed. New commercial developments in
protein biochips and related biosensors will also be examined.
View Cart
